Lastly, annotating samples as HRD and HRP based on defects in BRCA1/2 genes provided separation in progression free survival for the 25 PARPi-treated ovarian cancers (Supplementary Fig. S7). This evidence concerns the gene BRCA1 and ovarian cancer.